

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bolor *et al.*

Confirmation No.: 5216

Serial No.: 10/518,349

Group Art Unit: 1626

Filing Date: August 23, 2005

Examiner: (not yet assigned)

For: CHEMICAL PROCESS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR §1.97.

- ☒ Copies of the references are attached.
- ☐ Copies of the references were submitted in parent application Serial No. _____.
(37 CFR §1.98(d))
- ☒ A copy of the EPO Search Report which issued on European Application No. 03742050 is submitted herewith. All of the references cited in the Search Report are listed on the attached Form PTO-1449.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. 37 CFR §1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed **before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 CFR §1.114 (37 CFR §1.97(b)(4))**.
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in §1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final Office Action under §1.113 or
 - (2) a Notice of Allowance under §1.311,
- whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR §1.17(p) for submission of an Information Disclosure Statement under §1.97(c) (\$240.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final Office Action under §1.113, or a Notice of Allowance under §1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No. _____.

In accordance with the requirements of 37 CFR §1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR §1.97(d)(ii).
- ☐ The petition fee set forth in §1.17(i)(1) (\$130.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No. 07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully submitted,



Jennifer L. Fox
Attorney of Record
Registration No. 52,218

Date: February 12, 2007
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-6334
Facsimile: (919) 483-7988

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PU4806USw	SERIAL NO. 10518,349
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Bolor	
		FILING DATE August 23, 2005	GROUP 1626

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4	US-20020052388-A1	05-02-2002	Armistead et al.			
	5	US-3755332-A	08-28-1973	Wasley et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	6	WO-02059110-A	08-01-2002	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

7	AUWERS K., ET AL: "Über Raumisomere Acylderivate Substituierter Indazole"; Berichte der Deutschen Chemischen Gesellschaft; 1920; Vol. 53, No. 11; pp. 1211-1232;
8	BENCHIDI M., ET AL: "Synthese et Reactivité de Nitro Indazoles"; J. Het. Chem.; 1976; Vol. 15; pp. 1589-1603;
9	CHEUNG M., ET AL: "Efficient and Regioselective Synthesis of 2-Alkyl-2H-indazoles"; J. Org. Chem., 2003, Vol. 68, No. 10; pp. 4093-4095;
10	KAMETANI T., ET AL: "Synthetic Studies on Chemotherapeutics"; J. Het. Chem., 1977; Vol. 14; pp. 1175-1182;
11	SCHWAN T., ET AL: "Synthesis, Structure Elucidation and Antibacterial Activity of 6-Ethyl-6,8-dihydro-9-oxopyrazolo[3,4-f]quinoline-8-carboxylic Acid"; J. Het. Chem.; 1993; Vol. 20; pp. 1351-1353;

Examiner Signature	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	